Delivery Order SPE2DB22D1103-SPE2DB25FTME5
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $40,587.48 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Pediarix 0.5 mL syringes. The contract represents a firm fixed-price delivery order with an ultimate completion date of August 18, 2025, and carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill performance...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Pediarix 0.5 ML syringes valued at $2,753.62 with a completion date of September 2, 2025. This is a firm fixed-price, non-set-aside delivery order to be fulfilled at the contractor's Conshohocken, Pennsylvania facility. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $2,276.61 on August 8, 2025, for the supply of Pediarix 0.5 ML syringes. This non-competitive delivery order represents a firm fixed-price transaction with an ultimate completion date of August 11, 2025, with performance to be executed at the vendor's facility in Conshohocken, Pennsylvania. As a child contract, this delivery order is issued under AmerisourceBergen's broader contractual...
- The Defense Logistics Agency awarded a $1,299.69 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Pediarix 0.5 ML syringes. This firm fixed price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The vaccine product will be delivered to AmerisourceBergen's distribution facility in Conshohocken, Pennsylvania, with an...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,759.00 to AmerisourceBergen Drug Corp for the supply of Pediarix 0.5 ml syringes. This competitively awarded, firm fixed-price delivery order was issued on August 25, 2025, with an ultimate completion date of August 26, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Pediarix is a pediatric combination vaccine, and this order represents one of numerous pharmaceutical...
- The Defense Logistics Agency awarded a $5,151.24 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Pediarix 0.5 ML syringes. This non-set-aside, firm fixed price contract is classified as a delivery order and has an ultimate completion date of July 24, 2025. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Pediarix 0.5 ML syringes valued at $7,613.09. This is a firm fixed price, competitively awarded delivery order with an ultimate completion date of August 8, 2025, and represents a non-set-aside contract. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major...
- The Defense Logistics Agency awarded a $4,253.00 delivery order to AmerisourceBergen Drug Corp for Pediarix 0.5 mL syringes on July 10, 2025, with an ultimate completion date of July 11, 2025. This firm fixed-price contract, executed without a set-aside designation, represents a competitively awarded transaction for pediatric vaccination supplies to be performed at the contractor's Conshohocken, Pennsylvania facility. The delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a $10,577.34 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Pediarix 0.5 mL syringes. This firm fixed-price contract, with an ultimate completion date of August 5, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside designation. Performance will take place at AmerisourceBergen's corporate...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Pediarix 0.5 ML syringes, a pediatric vaccine product. This competitively awarded, non-set-aside contract is valued at $6,988.75 with a firm fixed price and an ultimate completion date of September 4, 2025. AmerisourceBergen will fulfill this order from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- SPE2DB22D1103Indefinite Delivery Contract
- SPE2DB22D1103-SPE2DB25FTME5Delivery Order
The Defense Logistics Agency awarded a $5,790.31 delivery order to AmerisourceBergen Drug Corp on May 8, 2025, for the supply of Pediarix 0.5 mL syringes, with an ultimate completion date of May 9, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, supplies a comprehensive range of medical products to support federal military and veteran healthcare systems through its prime contract vehicle with the DLA. The Pediarix vaccine delivery under this order supports the Defense Health Agency's medical supply chain requirements and represents the type of routine pharmaceutical commodity procurement executed through the company's global pharmaceutical support agreement. No set-aside designation was applied to this award, reflecting the competitively awarded status of the underlying IDC.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.8k | 5/8/25 |